Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NSAID continuation linked to less knee OA pain

Publish date:: July 29, 2020

Key clinical point: Continued meloxicam treatment was associated with better pain scores at 4 weeks compared with switching to placebo.

Major finding: WOMAC pain scores (0-20) were 6.7 for patients who continued meloxicam versus 7.8 in those who stopped and switched to a placebo.

Study details: The Stopping NSAIDs for Arthritis Pain multicenter randomized withdrawal trial conducted in 364 patients with knee osteoarthritis treated with meloxicam, or with placebo followed by cognitive behavioral therapy.

Disclosures: The lead author disclosed receiving research funding from the VA Office of Research and Development, the sponsor of the trial.

Citation:

Fraenkel L et al. JAMA Intern Med. 2020 Jul 20. doi: 10.1001/jamainternmed.2020.2821.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Osteoarthritis

Real acupuncture beat sham for osteoarthritis knee pain,

Stress tests before knee, hip replacement surgeries down, with no ill effects,

NSAID continuation linked to less knee OA pain,

Bisphosphonates may have limited ‘protective’ effect against knee OA progression,

Tramadol mortality risk in osteoarthritis could outweigh benefits,